Compare MPTI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | ACRS |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 311.0M |
| IPO Year | 2022 | 2015 |
| Metric | MPTI | ACRS |
|---|---|---|
| Price | $92.59 | $4.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $71.00 | $10.20 |
| AVG Volume (30 Days) | 56.4K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $54,417,000.00 | $1,683,000.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $12.15 | $4.24 |
| P/E Ratio | $135.36 | ★ N/A |
| Revenue Growth | ★ 11.03 | N/A |
| 52 Week Low | $36.38 | $1.34 |
| 52 Week High | $90.69 | $5.15 |
| Indicator | MPTI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 75.58 | 46.79 |
| Support Level | $60.13 | $4.15 |
| Resistance Level | N/A | $4.56 |
| Average True Range (ATR) | 4.19 | 0.21 |
| MACD | 1.14 | -0.05 |
| Stochastic Oscillator | 91.48 | 19.02 |
M-Tron Industries Inc is an electronic components manufacturer based in the United States. Along with its subsidiaries, the company is engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company serves markets in aerospace and defense, space, and avionics sectors. Its product offerings include microwave and millimeter-wave filters, crystal resonators, clock oscillators, voltage-controlled crystal oscillators, low noise amplifiers, couplers, attenuators, and switches, among others. Geographically, it derives maximum revenue from the domestic market, and the rest from Malaysia, Australia, Greece, and other countries.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.